Madrigal Pharmaceuticals (NASDAQ:MDGL) Price Target Lowered to $529.00 at Bank of America

Madrigal Pharmaceuticals (NASDAQ:MDGL) had its target price trimmed by Bank of America from $570.00 to $529.00 in a research note released on Friday morning,Benzinga reports. The brokerage currently has a neutral rating on the biopharmaceutical company’s stock.

MDGL has been the topic of several other reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Madrigal Pharmaceuticals in a research report on Thursday, January 22nd. Piper Sandler boosted their price objective on Madrigal Pharmaceuticals from $540.00 to $900.00 and gave the company an “overweight” rating in a research note on Friday, December 19th. B. Riley Financial raised their target price on shares of Madrigal Pharmaceuticals from $560.00 to $670.00 and gave the stock a “buy” rating in a research note on Thursday, December 11th. The Goldman Sachs Group reaffirmed a “buy” rating and set a $571.00 price target on shares of Madrigal Pharmaceuticals in a report on Wednesday, January 14th. Finally, Zacks Research cut shares of Madrigal Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Monday, January 12th. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $669.86.

Madrigal Pharmaceuticals Stock Performance

MDGL opened at $435.01 on Friday. The company’s 50 day moving average is $521.61 and its 200 day moving average is $481.31. The company has a current ratio of 3.44, a quick ratio of 3.26 and a debt-to-equity ratio of 0.54. The company has a market cap of $9.88 billion, a price-to-earnings ratio of -33.80, a PEG ratio of 6.21 and a beta of -1.01. Madrigal Pharmaceuticals has a 12-month low of $265.00 and a 12-month high of $615.00.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last announced its earnings results on Thursday, February 19th. The biopharmaceutical company reported ($2.57) EPS for the quarter, missing analysts’ consensus estimates of $0.04 by ($2.61). The business had revenue of $321.08 million for the quarter, compared to analysts’ expectations of $310.36 million. Madrigal Pharmaceuticals had a negative net margin of 30.08% and a negative return on equity of 42.55%. The firm’s quarterly revenue was up 210.8% on a year-over-year basis. During the same period in the prior year, the company posted ($2.71) earnings per share. On average, equities research analysts predict that Madrigal Pharmaceuticals will post -23.47 EPS for the current year.

Insiders Place Their Bets

In other Madrigal Pharmaceuticals news, Director Paul A. Friedman sold 24,800 shares of the business’s stock in a transaction on Wednesday, December 10th. The shares were sold at an average price of $552.18, for a total value of $13,694,064.00. Following the sale, the director owned 187,164 shares in the company, valued at $103,348,217.52. The trade was a 11.70% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Carole Huntsman sold 910 shares of the business’s stock in a transaction dated Monday, January 26th. The stock was sold at an average price of $493.78, for a total value of $449,339.80. Following the completion of the sale, the insider owned 9,122 shares in the company, valued at $4,504,261.16. This represents a 9.07% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 99,537 shares of company stock worth $53,485,702 over the last ninety days. 21.50% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. Eastern Bank raised its stake in Madrigal Pharmaceuticals by 32.3% during the fourth quarter. Eastern Bank now owns 86 shares of the biopharmaceutical company’s stock valued at $50,000 after purchasing an additional 21 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its position in shares of Madrigal Pharmaceuticals by 0.7% during the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 4,459 shares of the biopharmaceutical company’s stock valued at $1,349,000 after buying an additional 30 shares in the last quarter. Centaurus Financial Inc. lifted its holdings in shares of Madrigal Pharmaceuticals by 5.0% in the 3rd quarter. Centaurus Financial Inc. now owns 709 shares of the biopharmaceutical company’s stock valued at $325,000 after acquiring an additional 34 shares during the last quarter. Farther Finance Advisors LLC grew its position in Madrigal Pharmaceuticals by 34.6% in the fourth quarter. Farther Finance Advisors LLC now owns 140 shares of the biopharmaceutical company’s stock worth $82,000 after acquiring an additional 36 shares in the last quarter. Finally, Accent Capital Management LLC increased its stake in Madrigal Pharmaceuticals by 64.9% during the fourth quarter. Accent Capital Management LLC now owns 94 shares of the biopharmaceutical company’s stock worth $55,000 after acquiring an additional 37 shares during the last quarter. 98.50% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Madrigal Pharmaceuticals

Here are the key news stories impacting Madrigal Pharmaceuticals this week:

• Positive Sentiment: Rezdiffra commercial strength: Q4 net sales of roughly $321.1M (Q4) and $958.4M for full‑year 2025, more than 36,250 patients on therapy and nearly $989M in cash and marketable securities — evidence of strong revenue growth and a sizeable cash runway. Press Release
• Neutral Sentiment: Investor materials and transparency: company provided an earnings slide deck and held a conference call — useful for modeling future margins, guidance and pipeline milestones. Earnings Presentation
• Negative Sentiment: Large EPS miss and rising expenses: reported Q4 EPS of ($2.57) vs. consensus ~$0.04, driven by a wider loss as expenses surged despite revenue beating estimates — this prompted an immediate negative market reaction. Zacks Article
• Negative Sentiment: Analyst action: Bank of America cut its price target (from $570 to $529) and set a “neutral” rating, reducing near‑term upside expectations and likely contributing to selling pressure. Benzinga

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for cardiovascular, metabolic and liver diseases. The company’s pipeline centers on novel, liver-directed agents designed to address significant unmet medical needs, with an emphasis on nonalcoholic steatohepatitis (NASH) and related metabolic disorders.

The lead product candidate, resmetirom (MGL-3196), is an orally administered, selective thyroid hormone receptor-β agonist in Phase 3 development for the treatment of NASH.